The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL).
Lia Gore
Consultant or Advisory Role - Amgen
Stock Ownership - Amgen
Gerhard Zugmaier
Employment or Leadership Position - Amgen
Rupert Handgretinger
No relevant relationships to disclose
Franco Locatelli
Consultant or Advisory Role - Amgen
Tanya M. Trippett
No relevant relationships to disclose
Susan R. Rheingold
No relevant relationships to disclose
Peter Bader
No relevant relationships to disclose
Arndt Borkhardt
No relevant relationships to disclose
Todd Michael Cooper
No relevant relationships to disclose
Maureen Megan O'Brien
No relevant relationships to disclose
Christian M. Zwaan
Expert Testimony - Micromet (U)
Anja Fischer
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
James Whitlock
Consultant or Advisory Role - Amgen (U)
Research Funding - Amgen
Arend von Stackelberg
Consultant or Advisory Role - Amgen
Honoraria - Amgen